{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T03:40:04Z","timestamp":1780717204256,"version":"3.54.1"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"am","delay-in-days":665,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.ejmech.2021.113909","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T15:53:48Z","timestamp":1633967628000},"page":"113909","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Acridine\u2013O6-benzylguanine hybrids: Synthesis, DNA binding, MGMT inhibition and antiproliferative activity"],"prefix":"10.1016","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0404-7477","authenticated-orcid":false,"given":"Jaime","family":"Franco Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Fillion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Duchambon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Bombard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0424-0461","authenticated-orcid":false,"given":"Anton","family":"Granzhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2021.113909_bib1","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr. Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113909_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jocn.2018.05.002","article-title":"Ten-year survival in glioblastoma. A systematic review","volume":"54","author":"Tykocki","year":"2018","journal-title":"J.\u00a0Clin. Neurosci."},{"key":"10.1016\/j.ejmech.2021.113909_bib3","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11910-020-01042-6","article-title":"Novel therapies for glioblastoma","volume":"20","author":"Liu","year":"2020","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.ejmech.2021.113909_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.gendis.2016.04.007","article-title":"Temozolomide resistance in glioblastoma multiforme","volume":"3","author":"Lee","year":"2016","journal-title":"Genes Dis."},{"key":"10.1016\/j.ejmech.2021.113909_bib5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrc3185","article-title":"Balancing repair and tolerance of DNA damage caused by alkylating agents","volume":"12","author":"Fu","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2021.113909_bib6","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1038\/nsmb791","article-title":"DNA binding and nucleotide flipping by the human DNA repair protein AGT","volume":"11","author":"Daniels","year":"2004","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2021.113909_bib7","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2021.113909_bib8","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","article-title":"Potential strategies overcoming the temozolomide resistance for glioblastoma","volume":"58","author":"Jiapaer","year":"2018","journal-title":"Neurol. Med. Chir. (Tokyo)"},{"key":"10.1016\/j.ejmech.2021.113909_bib9","series-title":"Design of Hybrid Molecules for Drug Development","year":"2017"},{"key":"10.1016\/j.ejmech.2021.113909_bib10","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.ejmech.2016.08.039","article-title":"Hybrid molecules: the privileged scaffolds for various pharmaceuticals","volume":"124","author":"Shaveta","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib11","doi-asserted-by":"crossref","first-page":"35041","DOI":"10.18632\/oncotarget.25120","article-title":"Molecular analysis of the dual targeting of the epidermal growth factor receptor and the O6-methylguanine-DNA methyltransferase with a double arm hybrid molecule","volume":"9","author":"Rupp","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2021.113909_bib12","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1021\/acsmedchemlett.6b00358","article-title":"Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: BGCNU","volume":"8","author":"Wang","year":"2017","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2021.113909_bib13","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.bmc.2016.03.041","article-title":"Synthesis and antitumor activity evaluation of a novel combi-nitrosourea prodrug: designed to release a DNA cross-linking agent and an inhibitor of O6-alkylguanine-DNA alkyltransferase","volume":"24","author":"Sun","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib14","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1021\/jm049556d","article-title":"Synthesis and antitumor activity of methyltriazene prodrugs simultaneously releasing DNA-methylating agents and the antiresistance drug O6-benzylguanine","volume":"47","author":"Wanner","year":"2004","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib15","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.copbio.2007.09.006","article-title":"DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action","volume":"18","author":"Palchaudhuri","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.ejmech.2021.113909_bib16","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1016\/j.bmc.2014.05.030","article-title":"DNA binders in clinical trials and chemotherapy","volume":"22","author":"Ali","year":"2014","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib17","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.2217\/fon.09.127","article-title":"New hopes from old drugs: revisiting DNA-binding small molecules as anticancer agents","volume":"5","author":"Gurova","year":"2009","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2021.113909_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.semcancer.2019.09.021","article-title":"Repurposing quinacrine for treatment-refractory cancer","volume":"68","author":"Oien","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ejmech.2021.113909_bib19","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1478-811X-9-13","article-title":"Beyond DNA binding - a review of the potential mechanisms mediating quinacrine's therapeutic activities in parasitic infections, inflammation, and cancers","volume":"9","author":"Ehsanian","year":"2011","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2021.113909_bib20","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1002\/ijc.26158","article-title":"Quinacrine has anticancer activity in breast cancer cells through inhibition of topoisomerase activity","volume":"130","author":"Preet","year":"2012","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.113909_bib21","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1002\/cmdc.201100476","article-title":"Curaxins: a new family of non-genotoxic multitargeted anticancer agents","volume":"6","author":"Di Bussolo","year":"2011","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2021.113909_bib22","doi-asserted-by":"crossref","first-page":"17448","DOI":"10.1073\/pnas.0508888102","article-title":"Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-\u03baB-dependent mechanism of p53 suppression in tumors","volume":"102","author":"Gurova","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.113909_bib23","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/onc.2008.460","article-title":"9-Aminoacridine-based anticancer drugs target the PI3K\/AKT\/mTOR, NF-\u03baB and p53 pathways","volume":"28","author":"Guo","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2021.113909_bib24","doi-asserted-by":"crossref","first-page":"19162","DOI":"10.1074\/jbc.M109.091645","article-title":"Inhibition of NF-\u03baB signaling by quinacrine is cytotoxic to human colon carcinoma cell lines and is synergistic in combination with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) or Oxaliplatin","volume":"285","author":"Jani","year":"2010","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib25","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1158\/1535-7163.MCT-14-0013","article-title":"Quinacrine overcomes resistance to erlotinib by inhibiting FACT, NF-\u03baB, and cell-cycle progression in non\u2013small cell lung cancer","volume":"13","author":"Dermawan","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2021.113909_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002530","article-title":"Curaxins: anticancer compounds that simultaneously suppress NF-\u03baB and activate p53 by targeting FACT","volume":"3","author":"Gasparian","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2021.113909_bib27","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1021\/acsomega.6b00060","article-title":"Design, synthesis and evaluation of bifunctional acridinine naphthalenediimide redox-active conjugates as antimalarials","volume":"1","author":"Dana","year":"2016","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2021.113909_bib28","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1039\/C8MD00384J","article-title":"Medicinal chemistry of acridine and its analogues","volume":"9","author":"Prasher","year":"2018","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2021.113909_bib29","first-page":"47","article-title":"Efficient and versatile chemical tools for cleavage of abasic sites in DNA","volume":"21","author":"Belmont","year":"1997","journal-title":"New J. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib30","doi-asserted-by":"crossref","first-page":"5153","DOI":"10.1021\/jm9901428","article-title":"Abasic site recognition in DNA as a new strategy to potentiate the action of anticancer alkylating drugs?","volume":"42","author":"Belmont","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib31","doi-asserted-by":"crossref","first-page":"9471","DOI":"10.1021\/jm400794z","article-title":"Developing bivalent ligands to target CUG triplet repeats, the causative agent of myotonic dystrophy type 1","volume":"56","author":"Zimmerman","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib32","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1093\/nar\/gkr415","article-title":"Selective inhibition of MBNL1-CCUG interaction by small molecules toward potential therapeutic agents for myotonic dystrophy type 2 (DM2)","volume":"39","author":"Wong","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.113909_bib33","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/jcp.1040990107","article-title":"T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in\u00a0vitro","volume":"99","author":"Stein","year":"1979","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ejmech.2021.113909_bib34","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1023\/A:1026528926482","article-title":"Expression of multidrug resistance-associated protein (MRP) in human gliomas","volume":"49","author":"Mohri","year":"2000","journal-title":"J.\u00a0Neurooncol."},{"key":"10.1016\/j.ejmech.2021.113909_bib35","first-page":"735","article-title":"Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin","volume":"2","author":"Bobola","year":"1996","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113909_bib36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1471-4159.2005.03583.x","article-title":"O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells","volume":"96","author":"Hermisson","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2021.113909_bib37","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1021\/tx9700580","article-title":"Substrate specificity of human O6-methylguanine-DNA methyltransferase for O6-benzylguanine derivatives in oligodeoxynucleotides","volume":"10","author":"Terashima","year":"1997","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejmech.2021.113909_bib38","doi-asserted-by":"crossref","first-page":"7144","DOI":"10.1021\/jm800675p","article-title":"Substitution of aminomethyl at the meta-position enhances the inactivation of O6-alkylguanine-DNA alkyltransferase by O6-benzylguanine","volume":"51","author":"Pauly","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib39","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1021\/jm00101a028","article-title":"Structural features of substituted purine derivatives compatible with depletion of human O6-alkylguanine-DNA alkyltransferase","volume":"35","author":"Moschel","year":"1992","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib40","first-page":"3367","article-title":"Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents","volume":"51","author":"Moschel","year":"1991","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113909_bib41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.3390\/molecules21070823","article-title":"Identification of the structural features of guanine derivatives as MGMT inhibitors using 3D-QSAR modeling combined with molecular docking","volume":"21","author":"Sun","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2021.113909_bib42","doi-asserted-by":"crossref","first-page":"9955","DOI":"10.1073\/pnas.0401923101","article-title":"Labeling of fusion proteins with synthetic fluorophores in live cells","volume":"101","author":"Keppler","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.113909_bib43","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nbt765","article-title":"A\u00a0general method for the covalent labeling of fusion proteins with small molecules in\u00a0vivo","volume":"21","author":"Keppler","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2021.113909_bib44","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0223-5234(00)00170-7","article-title":"Synthesis and antiproliferative activity of some variously substituted acridine and azacridine derivatives","volume":"35","author":"Ferlin","year":"2000","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1002\/(SICI)1099-0682(199903)1999:3<557::AID-EJIC557>3.0.CO;2-Y","article-title":"Synthesis of two acridine conjugates of the bis(phenanthroline) ligand \u201cClip-Phen\u201d and evaluation of the nuclease activity of the corresponding copper complexes","author":"Ross","year":"1999","journal-title":"Eur. J. Inorg. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib46","doi-asserted-by":"crossref","DOI":"10.1021\/ja01150a600","article-title":"New compounds. Certain quinolyl and acridyl derivatives of \u03b2-alanine","volume":"73","author":"Humphlett","year":"1951","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.113909_bib47","doi-asserted-by":"crossref","first-page":"5265","DOI":"10.1021\/jm9708644","article-title":"Inactivation of O6-Alkylguanine-DNA alkyltransferase. 1. Novel O6-hetarylmethyl)guanines having basic rings in the side chain","volume":"41","author":"McElhinney","year":"1998","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib48","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1039\/b207902j","article-title":"Novel cryptands containing thiourea units as a part of the macrocyclic framework","volume":"1","author":"Lukyanenko","year":"2002","journal-title":"J.\u00a0Chem. Soc. Perkin"},{"key":"10.1016\/j.ejmech.2021.113909_bib49","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1021\/bi00411a016","article-title":"Heterodimeric molecules including nucleic acid bases and 9-aminoacridine: spectroscopic studies, conformations, and interactions with DNA","volume":"27","author":"Constant","year":"1988","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2021.113909_bib50","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1021\/ja00367a019","article-title":"Synthetic models related to DNA intercalating molecules: comparison between quinacrine and chloroquine in their ring-ring interaction with adenine and thymine","volume":"104","author":"Bolte","year":"1982","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2021.113909_bib51","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1351\/PAC-REP-10-09-31","article-title":"Standards for photoluminescence quantum yield measurements in solution (IUPAC Technical Report)","volume":"83","author":"Brouwer","year":"2011","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib52","series-title":"Highlights Bioorganic Chem. Methods Appl.","first-page":"172","article-title":"Evaluation of the DNA-binding properties of cationic dyes by absorption and emission spectroscopy","author":"Ihmels","year":"2004"},{"key":"10.1016\/j.ejmech.2021.113909_bib53","series-title":"Methods Enzymol.","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/S0076-6879(01)40418-6","article-title":"Linear and circular dichroism of drug-nucleic acid complexes","author":"Eriksson","year":"2001"},{"key":"10.1016\/j.ejmech.2021.113909_bib54","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1093\/nar\/29.12.2558","volume":"29","author":"Kreklau","year":"2001","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2021.113909_bib55","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1074\/jbc.M111.293605","article-title":"Acridine yellow G blocks glioblastoma growth via dual inhibition of epidermal growth factor receptor and protein kinase C kinases","volume":"287","author":"Qi","year":"2012","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib56","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1002\/cbic.201600652","article-title":"DNA-targeted inhibition of MGMT","volume":"18","author":"Marsoner","year":"2017","journal-title":"ChemBioChem"},{"key":"10.1016\/j.ejmech.2021.113909_bib57","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.1021\/jm030266r","article-title":"A\u00a0specific mechanism of nonspecific inhibition","volume":"46","author":"McGovern","year":"2003","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib58","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1016\/S0006-2952(97)00060-9","article-title":"Effect of DNA on the inactivation of O6-alkylguanine-DNA alkyltransferase by 9-substituted O6-benzylguanine derivatives","volume":"53","author":"Pegg","year":"1997","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113909_bib60","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1073\/pnas.87.14.5368","article-title":"Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents","volume":"87","author":"Dolan","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2021.113909_bib61","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1021\/acs.molpharmaceut.5b00341","article-title":"Multidrug efflux pumps attenuate the effect of MGMT inhibitors","volume":"12","author":"Tomaszowski","year":"2015","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2021.113909_bib62","doi-asserted-by":"crossref","first-page":"e0224137","DOI":"10.1371\/journal.pone.0224137","article-title":"Statistical determination of synergy based on Bliss definition of drugs independence","volume":"14","author":"Demidenko","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.113909_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.149","article-title":"Analysis of drug combinations: current methodological landscape","volume":"3","author":"Foucquier","year":"2015","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ejmech.2021.113909_bib64","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3389\/fphar.2017.00158","article-title":"An introduction to terminology and methodology of chemical synergy\u2014perspectives from across disciplines","volume":"8","author":"Roell","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113909_bib65","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113909_bib66","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2021.113909_bib67","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0152684","article-title":"Fluorogenic real-time reporters of DNA repair by MGMT, a clinical predictor of antitumor drug response","volume":"11","author":"Beharry","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2021.113909_bib68","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/nrc2523","article-title":"\u03b3H2AX and cancer","volume":"8","author":"Bonner","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2021.113909_bib69","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1158\/0008-5472.CAN-18-3394","article-title":"Temozolomide sensitizes MGMT-deficient tumor cells to ATR inhibitors","volume":"79","author":"Jackson","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2021.113909_bib70","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3389\/fonc.2019.00485","article-title":"C8-Substituted imidazotetrazine analogs overcome temozolomide resistance by inducing DNA adducts and DNA damage","volume":"9","author":"Yang","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2021.113909_bib71","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4161\/cbt.8.5.7740","article-title":"Diversity of DNA damage response of astrocytes and glioblastoma cell lines with various p53 status to treatment with etoposide and temozolomide","volume":"8","author":"Sato","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2021.113909_bib73","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/S0968-0896(01)00097-9","article-title":"Potentiation of BCNU cytotoxicity by molecules targeting abasic lesions in DNA","volume":"9","author":"Alarcon","year":"2001","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib74","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0960-894X(01)00310-9","article-title":"Diaminopurine-acridine heterodimers for specific recognition of abasic site containing DNA. Influence on the biological activity of the position of the linker on the purine ring","volume":"11","author":"Alarcon","year":"2001","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113909_bib75","doi-asserted-by":"crossref","first-page":"4721","DOI":"10.1002\/ejoc.200700207","article-title":"Targeting abasic sites in DNA by aminoalkyl-substituted carboxamidoacridizinium derivatives and acridizinium\u2013adenine conjugates","author":"Benner","year":"2007","journal-title":"Eur. J. Org Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib76","doi-asserted-by":"crossref","first-page":"625899","DOI":"10.3389\/fonc.2021.625899","article-title":"Study of combinatorial drug synergy of novel acridone derivatives with temozolomide using in-silico and in-vitro methods in the treatment of drug-resistant glioma","volume":"11","author":"Chakravarty","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2021.113909_bib77","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.dnarep.2011.09.007","article-title":"6-Carboxyfluorescein and structurally similar molecules inhibit DNA binding and repair by O6-alkylguanine DNA alkyltransferase","volume":"10","author":"Melikishvili","year":"2011","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2021.113909_bib78","doi-asserted-by":"crossref","DOI":"10.1289\/EHP6664","article-title":"Cytotoxicity burst? Differentiating specific from nonspecific effects in Tox21 in\u00a0vitro reporter gene assays","volume":"128","author":"Escher","year":"2020","journal-title":"Environ. Health Perspect."},{"key":"10.1016\/j.ejmech.2021.113909_bib79","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/ijc.31912","article-title":"Thioridazine inhibits autophagy and sensitizes glioblastoma cells to temozolomide","volume":"144","author":"Johannessen","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejmech.2021.113909_bib80","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.bmcl.2018.02.005","article-title":"Synthesis, spectroscopic studies and biological evaluation of acridine derivatives: the role of aggregation on the photodynamic efficiency","volume":"28","author":"Felip-Le\u00f3n","year":"2018","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2021.113909_bib81","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1002\/j.1460-2075.1996.tb00778.x","article-title":"The nuclear targeting and nuclear retention properties of a human DNA repair protein O6-methylguanine-DNA methyltransferase are both required for its nuclear localization: the possible implications","volume":"15","author":"Lim","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2021.113909_bib82","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s002800050427","article-title":"Intracellular localization and intercellular heterogeneity of the human DNA repair protein O6-methylguanine-DNA methyltransferase","volume":"37","author":"Belanich","year":"1996","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2021.113909_bib83","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2021.113909_bib84","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1021\/ci500004h","article-title":"AlzPlatform: an Alzheimer's disease domain-specific chemogenomics knowledgebase for polypharmacology and target identification research","volume":"54","author":"Liu","year":"2014","journal-title":"J.\u00a0Chem. Inf. Model."},{"key":"10.1016\/j.ejmech.2021.113909_bib85","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"The blood\u2013brain barrier and blood\u2013tumour barrier in brain tumours and metastases","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2021.113909_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00739","article-title":"Blood-brain barrier, blood-brain tumor barrier, and fluorescence-guided neurosurgical oncology: delivering optical labels to brain tumors","volume":"10","author":"Belykh","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2021.113909_bib87","doi-asserted-by":"crossref","first-page":"5448","DOI":"10.1021\/jm990386s","article-title":"Inhibition of Trypanosoma cruzi trypanothione reductase by acridines: kinetic studies and structure-activity relationships","volume":"42","author":"Bonse","year":"1999","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2021.113909_bib88","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1021\/acschembio.8b01083","article-title":"Covalent ligand screening uncovers a RNF4 E3 ligase recruiter for targeted protein degradation applications","volume":"14","author":"Ward","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2021.113909_bib89","unstructured":"Lijiao Z., Ruizeng P., Ting R., Rugang Z., Hufen Z., Low-oxygen Activated Joint Chloroethane Nitrourea Compound and Preparation Method and Application, 2016. Patent CN105503874A."},{"key":"10.1016\/j.ejmech.2021.113909_bib90","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/ar030113y","article-title":"A\u00a0fluorescent intercalator displacement assay for establishing DNA binding selectivity and affinity","volume":"37","author":"Tse","year":"2004","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2021.113909_bib91","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1006\/abbi.1993.1027","article-title":"Kinetic and DNA-binding properties of recombinant human O6-methylguanine-DNA methyltransferase","volume":"300","author":"Chan","year":"1993","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2021.113909_bib93","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41374-017-0009-0","article-title":"\u03b2-Ecdysterone protects SH-SY5Y cells against \u03b2-amyloid-induced apoptosis via c-Jun N-terminal kinase-and Akt-associated complementary pathways","volume":"98","author":"Xu","year":"2018","journal-title":"Lab. Invest."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007583?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523421007583?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:38:36Z","timestamp":1759329516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523421007583"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":90,"alternative-id":["S0223523421007583"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113909","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acridine\u2013O6-benzylguanine hybrids: Synthesis, DNA binding, MGMT inhibition and antiproliferative activity","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2021.113909","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"113909"}}